Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROMETRIX, INC.

(NURO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NeuroMetrix : Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in the opinion filed as Exhibit 5.1) (Form 8-K)

08/13/2021 | 08:02am EDT

One Financial Center

Boston, MA 02111

617 542 6000

mintz.com

August 13, 2021

NeuroMetrix, Inc.

4b Gill Street

Woburn, MA 01801

Ladies and Gentlemen:

This opinion is furnished to you in connection with the filing of a prospectus supplement, dated August 13, 2021 (the 'Prospectus Supplement'), to a Registration Statement on Form S-3, Registration No. 333-229349 (the 'Registration Statement') filed by NeuroMetrix, Inc., a Delaware corporation (the 'Company'), with the Securities and Exchange Commission (the 'Commission') under the Securities Act of 1933, as amended (the 'Securities Act'), with respect to the sale of shares (the 'Shares') of the Company's common stock, par value $0.0001 per share, up to an aggregate offering amount of $14,000,000, pursuant to the At Market Issuance Sales Agreement (the 'Sales Agreement'), dated February 19, 2020, by and between the Company and Ladenburg Thalmann & Co. Inc. The Shares are to be sold pursuant to the Prospectus Supplement and the base prospectus included in the Registration Statement, dated March 8, 2019 (together with the Prospectus Supplement, the 'Prospectus'). The Sales Agreement was filed as an exhibit to a Current Report on Form 8-K on February 19, 2020 and incorporated by reference into the Registration Statement.

In connection with this opinion, we have examined the Company's Amended and Restated Certificate of Incorporation, as amended to date, and Amended and Restated By-Laws, both as currently in effect; the minutes of all pertinent meetings of the board of directors of the Company relating to the Registration Statement, the Prospectus and the transactions contemplated thereby; such other records of the corporate proceedings of the Company and certificates of the Company's officers as we deemed relevant for the purposes of rendering the opinions in this letter; the Registration Statement and the exhibits thereto filed with the Commission; the Prospectus; and the Sales Agreement.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies.

Based upon the foregoing, and subject to the limitations set forth below, we are of the opinion that the Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by the Sales Agreement and a Placement Notice (as defined in the Sales Agreement), will be duly and validly issued, fully paid and non-assessable.

Our opinion is limited to the General Corporation Law of the State of Delaware and the United States federal laws, and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be reliable.

BOSTON LONDON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO WASHINGTON

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

MINTZ

August 13, 2021

Page 2

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

We hereby consent to the filing of this opinion with the Commission as an exhibit to a Current Report on Form 8-K (and its incorporation by reference into the Registration Statement) in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to the use of this Firm's name therein and in the Prospectus under the caption 'Legal Matters.' In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,
/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Disclaimer

NeuroMetrix Inc. published this content on 13 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 August 2021 12:01:08 UTC.


© Publicnow 2021
All news about NEUROMETRIX, INC.
10/14NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Ca..
GL
10/07NeuroMetrix Shares Rise 10% After Submitting De Novo Request for Quell
DJ
10/07NEUROMETRIX : Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Sy..
AQ
10/07NEUROMETRIX : Files for FDA De Novo Clearance for Quell Device to Treat Symptoms of Fibrom..
MT
10/06NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia S..
GL
10/06NeuroMetrix Announces Submission of U.S. Food and Drug Administration De Novo Request f..
CI
10/05NEUROMETRIX : Announces Participation in the Center to Stream Healthcare In Place (C2SHIP)..
AQ
08/27Top Premarket Gainers
MT
08/13INSIDER TRENDS : Insider Sale at NeuroMetrix Scaling Back 90-Days of Buying
MT
08/13NEUROMETRIX : Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in ..
PU
More news
Financials (USD)
Sales 2020 7,38 M - -
Net income 2020 -2,09 M - -
Net cash 2020 4,17 M - -
P/E ratio 2020 -4,55x
Yield 2020 -
Capitalization 51,2 M 51,2 M -
EV / Sales 2019 0,28x
EV / Sales 2020 1,06x
Nbr of Employees 20
Free-Float 99,4%
Chart NEUROMETRIX, INC.
Duration : Period :
NeuroMetrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROMETRIX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Shai N. Gozani Chairman, President & Chief Executive Officer
Thomas T. Higgins Chief Financial Officer, Treasurer & Senior VP
David E. Goodman Independent Director
Nancy E. Katz Independent Director
David van Avermaete Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NEUROMETRIX, INC.187.97%53
ABBOTT LABORATORIES12.62%211 568
MEDTRONIC PLC3.97%164 458
BECTON, DICKINSON AND COMPANY-1.33%69 710
HOYA CORPORATION22.25%57 064
DEXCOM, INC.50.53%53 217